Filing Flows › Arcus Biosciences (RCUS) › Q2 2026
Arcus Biosciences (RCUS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Arcus Biosciences (RCUS) reported revenue of $41.0M for the second quarter 2026 (Q2 2026), -74% from a year earlier and +141% from the quarter before. Operating margin was -234.1%, net loss $91.0M (222.0% of revenue).
Arcus Biosciences, Q2 2026: revenue $41.0M (-74% year over year), operating margin -234.1%, net loss $91.0M, operating cash flow −$119M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41.0M | +141% | -74% |
| Operating profit | −$96.0M | — | — |
| Net earnings | −$91.0M | — | — |
| Operating cash flow | −$119M | — | — |
What changed
Revenue was $41.0M in Q2 2026, down 74% year over year and up 141% from the previous quarter. Other collaboration was the largest line at 61% of revenue. License and development services lost $136.0M year over year (down 89%), 114% of the total change.
Operating costs exceeded revenue by $96.0M, an operating margin of -234.1%. Total costs fell 18% while revenue fell 74%. The quarter ended with a net loss of $91.0M, narrower than the previous quarter's $128.0M loss.
Operating cash flow was −$119.0M. Non-cash charges added back $3.0M of depreciation and amortization and $15.0M of share-based compensation. Working capital and other items used $46.0M.
Questions
What was Arcus Biosciences' revenue in the second quarter 2026?
Arcus Biosciences (RCUS) reported revenue of $41.0M for the second quarter 2026 (Q2 2026), -74% from a year earlier and +141% from the quarter before.
Was Arcus Biosciences profitable in the second quarter 2026?
Operating loss was $96.0M (-234.1% of revenue) and net loss $91.0M.
Source: Arcus Biosciences 10-Q on SEC EDGAR.